Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Mcsaf Inside Oncology is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both actions are assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly centralized prosecution profile. This concentration suggests that the company's current patent efforts are focused on a very specific technical area within oncology. Such a narrow focus allows for a deeply specialized prosecution strategy that aligns with the specific technical requirements of the assigned unit. Practitioners can prioritize resources to address the specific technical niche identified by this art unit assignment.
CANELLA, KAREN A is the busiest examiner, overseeing both of the 2 pending office actions. Because all pending actions are handled by 1 distinct examiner, the prosecution strategy is entirely dependent on this individual's review and interpretation of the pharmaceutical claims. Practitioners should focus on building a consistent dialogue with this examiner across the 2 pending actions. This centralized approach simplifies the management of the portfolio, as the legal team only needs to account for the preferences and precedents of 1 distinct examiner within the oncology field. Maintaining a unified strategy across both actions can help in securing consistent outcomes for the oncology-related claims.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANELLA, KAREN A | 2 | 62.3% | +32.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802274 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CANELLA, KAREN A | 53d overdue |
| 18333261 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18333261 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CANELLA, KAREN A | 1643 | §103§112DP | Non-Final OA | — | Pending | Jun 12, 2023 |
| 17802274 | ANTI-CD56 ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THERAPY | CANELLA, KAREN A | 1643 | §103DP | Final Rejection | 53d overdue | Pending | Aug 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMcsaf Inside Oncology has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Karen A Canella has the most, with 2 of Mcsaf Inside Oncology's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
